

New thieno:imidazole derivatives - are angiotensin-II antagonists for treating hypertension, cardiac insufficiency, angina pectoris and arteriosclerosis

Patent Number: DE4034728
Publication date: 1992-05-07
Inventor(s): KUHNKE JOACHIM DR (DE); SCHOELLKOPF KLAUS DR (DE); BECKMANN ROLF DR (DE); GRAF HERMANN DR (DE)
Applicant(s): SCHERING AG (DE)
Requested Patent: DE4034728
Application Number: DE19904034728 19901030
Priority Number(s): DE19904034728 19901030
IPC Classification: A61K31/41; A61K31/445; A61K31/495; C07D495/04; C07D495/14; C07D495/18; C07D497/18; C07D513/18
ECC Classification: C07D495/04
Equivalents:

Abstract

Thienoimidazole derivs. of formula (I) and their acid and base addn. salts are new, where A is (a)-(c), R1 = H, 1-8C alkyl, 3-6C alkenyl, 3-6C alkyanyl (these last 3 gps. opt. substd. with one halogen, one OR5 or 2 benzyl, R2 = (d) or (e), G = (f)-(k), the dotted line is a double or single bond B is -(CH2)p-, CR116R17, -C (R16R17)CH2-, -CH2C(R16R17)- or C=CR19R19, R3 and R4 = each H, F, Cl, Br, 1-6C alkyl, 2-6C alkenyl, 2-6C alkyanyl, 1-6C perfluoroalkyl, 3-6C cycloalkyl, 1-4C alkoxy, CN, C6F5, -(CH2)nOR5, -(CH2)nOCOR5, -(CH2)mCOR6, -(CH2)mNHCOR5, -(CH2)mNHOOR7, -NR8R9 or -(CH2)mR11 or in the case of A = (a) or (CH2)pCH2Z-, -CH=CH-W or =CHWCH=, R5 = H or 1-4C alkyl, R6 = H, 1-6C alkyl, 3-6C cycloalkyl, 1-6C perfluoroalkyl, Ph, NR8R9 or OR5, R7 = 1-4C alkyl or benzyl, R8 and R9 = each H, 1-4C alkyl, Ph, benzyl or C6H4R12, R12 = H, F, Cl, Br, -NR5R10, 1-4C alkoxy, OH or CO2R5, R13 = CO2R5, -NHSO2R20 or (m), R14 and R15 = each H, F, Cl, Br, CN or OR5, R16 and R17 = each H, 1-4C alkyl, 3-4C alkenyl, 3-4C alkynyl or -CH2CH2-, R18 and R19 = each H, 1-4C alkyl or -(CH2)r-, R20 = 1-6C alkyl or 1-6C perfluoroalkyl, T = CH2, O or NR10, W = O, S, NH or CH=CH, X = O, S or NH, Y = O or NH, Z = CH2, O, S or NR10, l = 3, 4, m = 0-3, n = 1-6, p = 1-2, r = 4=5.

USE/ADVANTAGE - (I) are competitive angiotensin II antagonists which bond with high affinity on angiotensin II receptors and inhibit angiotensin II induced effects both in vivo and in vitro. (I) can therefore be used to treat disorders of the heart and circulation e.g. hypertension, cardiac insufficiency, angina pectoris and arteriosclerosis. Suitable doses are 0.01-50 mg/kg.

Data supplied from the esp@cenet.database.com - 10